|Bid||4.5600 x 3100|
|Ask||4.5700 x 900|
|Day's Range||4.5000 - 4.7800|
|52 Week Range||1.0300 - 13.4000|
|Beta (5Y Monthly)||2.48|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The core reason is that most of these companies are trading at a mere fraction of the commercial potential of their lead product candidates. On the rare occasion, however, these risky equities do sprout wings and learn to fly because of a surprise win in the clinic, a buyout agreement, or a licensing deal with a bigger pharma -- thus producing outsize gains for early shareholders. Adaptimmune Therapeutics (NASDAQ: ADAP) and Trillium Therapeutics (NASDAQ: TRIL) could both turn out to be diamonds in the rough.
Image source: The Motley Fool. Adaptimmune Therapeutics PLC (NASDAQ: ADAP)Q3 2020 Earnings CallNov 6, 2020, 8:00 p.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorLadies and gentlemen, thank you for standing by, and welcome to Adaptimmune's Third Quarter 2020 Financial Results and Business Update.
Adaptimmune Therapeutics (NASDAQ: ADAP), a clinical-stage cancer specialist, is having another off day today. For the week, Adaptimmune's stock is now down by over 20%. Earlier today, Adaptimmune announced the early release of an abstract for an upcoming presentation at the virtual Society for the Immunotherapy of Cancer conference on Nov. 11, 2020.